<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03401372</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-AL2017</org_study_id>
    <nct_id>NCT03401372</nct_id>
  </id_info>
  <brief_title>BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients</brief_title>
  <official_title>Comparison of Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy With or Without Doxycycline in Newly Diagnosed Mayo Stage II-III Light Chain Amyloidosis Patients: A Multi-center Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jian Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Survival of intermediate and high-risk primary light chain amyloidosis (pAL) remains poor due
      to high mortality within 3-6 months of diagnosis. Rapidly effective regimens such as
      bortezomib, cyclophosphamide and dexamethasone (BCD) still failed to overcome the poor
      prognosis in very advanced pAL amyloidosis patients. Recently, doxycycline was demonstrated
      to induce disruption of fibril formation and reduce the number of intact fibrils in
      transgenic mouse model of pAL amyloidosis. Furthermore, case-control study suggested that
      adjuvant oral doxycycline could improve response and survival in cardiac pAL amyloidosis,
      which necessities further confirmation through a randomized trial. Therefore, we designed a
      multi-center randomized open-label controlled study to investigate the efficacy and safety of
      co-administration of oral doxycycline with BCD regimen in treatment-naïve patients with Mayo
      stage II-III pAL amyloidosis. The primary outcome progression-free survival, and secondary
      endpoints including overall survival, hematologic response, organ response and toxicity of
      doxycycline will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2018</start_date>
  <completion_date type="Anticipated">April 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>The patients are assessed after each cycle of chemotherapy following treatment initiation until progression, relapse, death or study closure at 24-month follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>The patients are assessed after each cycle of chemotherapy following treatment initiation until progression, relapse, death or study closure at 24-month follow-up. If the primary endpoint has reached, patients will also be followed up every 3 months thereafter until death or study closure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic response</measure>
    <time_frame>2 years</time_frame>
    <description>The patients are assessed after each cycle of chemotherapy following treatment initiation until progression, relapse, death or study closure at 24-month follow-up. If the primary endpoint has reached, patients will also be followed up every 3 months thereafter until death or study closure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ response</measure>
    <time_frame>2 years</time_frame>
    <description>The patients are assessed after each cycle of chemotherapy following treatment initiation until progression, relapse, death or study closure at 24-month follow-up. If the primary endpoint has reached, patients will also be followed up every 3 months thereafter until death or study closure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Adverse events are collected until 30 days after last dose of doxycycline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Amyloidosis; Systemic</condition>
  <arm_group>
    <arm_group_label>Doxycycline/BCD chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bortezomib-cyclophosphamide-dexamethasone chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Oral doxycycline 100mg twice daily</description>
    <arm_group_label>Doxycycline/BCD chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>1.3mg/m2 of intravenous bortezomib on days 1, 8, 15 and 22 of a 35-day cycle</description>
    <arm_group_label>Doxycycline/BCD chemotherapy</arm_group_label>
    <arm_group_label>BCD chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>300mg/m2 cyclophosphamide on days 1, 8 and 15 of a 35-day cycle</description>
    <arm_group_label>Doxycycline/BCD chemotherapy</arm_group_label>
    <arm_group_label>BCD chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle</description>
    <arm_group_label>Doxycycline/BCD chemotherapy</arm_group_label>
    <arm_group_label>BCD chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years old adults.

          -  Biopsy proved treatment-naïve pAL amyloidosis.

          -  Mayo 2004 stage II-III.

          -  dFLC &gt; 40mg/L.

          -  Patient must provide informed consent.

        Exclusion Criteria:

          -  Co-morbidity of uncontrolled infection.

          -  Co-morbidity of grade 2 or 3 atrioventricular block.

          -  Co-morbidity of sustained or recurrent nonsustained ventricular tachycardia.

          -  Co-morbidity of other active malignancy.

          -  Co-diagnosis of multiple myeloma or waldenstrom macroglobulinemia.

          -  Grade 2 or higher neuropathy according to National Cancer Institute Common Terminology
             Criteria for Adverse Events version 3.0.

          -  Allergic history of doxycycline.

          -  Neutrophil ＜1×10E9/L，hemoglobin ＜ 7g/dL，or platelet ＜ 75×10E9/L.

          -  Severely compromised hepatic or renal function: ALT or AST &gt; 2.5 × ULN, total
             bilirubin &gt; 1.5mg/dL，or eGFR ＜ 60mL/min.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Li, MD</last_name>
    <phone>+86-18610852525</phone>
    <email>lijian@pumch.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaini Shen, MD</last_name>
    <phone>+86-13693339884</phone>
    <email>shenkaini3@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Li, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ward JE, Ren R, Toraldo G, Soohoo P, Guan J, O'Hara C, Jasuja R, Trinkaus-Randall V, Liao R, Connors LH, Seldin DC. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011 Dec 15;118(25):6610-7. doi: 10.1182/blood-2011-04-351643. Epub 2011 Oct 12.</citation>
    <PMID>21998211</PMID>
  </reference>
  <results_reference>
    <citation>Shen KN, Li J. [Light Chain Amyloidosis: an Update for Treatment]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Jun;23(3):910-4. doi: 10.7534/j.issn.1009-2137.2015.03.059. Chinese.</citation>
    <PMID>26117060</PMID>
  </results_reference>
  <results_reference>
    <citation>Feng J, Huang XF, Zhang CL, Shen KN, Zhang CL, Sun J, Tian Z, Cao XX, Zhang L, Zhou DB, Li J. [Analysis of clinical characteristics and outcome of patients with very high risk primary immunoglobulin light-chain amyloidosis]. Zhonghua Xue Ye Xue Za Zhi. 2017 Feb 14;38(2):107-111. doi: 10.3760/cma.j.issn.0253-2727.2017.02.005. Chinese.</citation>
    <PMID>28279033</PMID>
  </results_reference>
  <results_reference>
    <citation>Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004 Sep 15;22(18):3751-7.</citation>
    <PMID>15365071</PMID>
  </results_reference>
  <results_reference>
    <citation>Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012 May 10;119(19):4391-4. doi: 10.1182/blood-2011-11-390930. Epub 2012 Feb 13.</citation>
    <PMID>22331188</PMID>
  </results_reference>
  <results_reference>
    <citation>Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Hawkins PN, Wechalekar AD. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia. 2014 Dec;28(12):2304-10. doi: 10.1038/leu.2014.218. Epub 2014 Jul 16.</citation>
    <PMID>25027514</PMID>
  </results_reference>
  <results_reference>
    <citation>Kastritis E, Roussou M, Gavriatopoulou M, Migkou M, Kalapanida D, Pamboucas C, Kaldara E, Ntalianis A, Psimenou E, Toumanidis ST, Tasidou A, Terpos E, Dimopoulos MA. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015 Apr;90(4):E60-5. doi: 10.1002/ajh.23936. Epub 2015 Mar 9.</citation>
    <PMID>25580702</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Jian Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Primary light chain amyloidosis</keyword>
  <keyword>Doxycycline</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Progression-free survival</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Organ response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

